1. Meaningful cognitive change for the Minimal Assessment of Cognitive Function in Multiple Sclerosis.
- Author
-
Portaccio E, Grossi P, Bellomi F, Bianchi V, Cilia S, Falautano M, Goretti B, Niccolai C, Pietrolongo E, Viterbo RG, and Amato MP
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Cognition physiology, Young Adult, Multiple Sclerosis complications, Multiple Sclerosis physiopathology, Neuropsychological Tests standards, Cognitive Dysfunction diagnosis, Cognitive Dysfunction etiology, Cognitive Dysfunction physiopathology
- Abstract
Background: There is limited information on interpretation of cognitive changes over time in multiple sclerosis (MS)., Objective: This study aimed to provide normative data for the assessment of statistically meaningful change in all tests of the Minimal Assessment of Cognitive Function in MS (MACFIMS)., Methods: We applied the reliable change methodology to a healthy Italian cohort, assessed with two alternate versions of the MACFIMS 1 year apart. We calculated confidence intervals of retest score variance using the reliable change index (RCI). Moreover, multivariable linear regression models adjusted for age, sex, education, and baseline score were built to calculate the regression-based change index (RB-CI)., Results: Overall, 200 healthy individuals were enrolled. Thresholds for interpreting change in each test were calculated. In the multivariable models, baseline score was associated with retest score in all tests ( B from 0.439 to 0.760; p < 0.001). RB-CI can be calculated with data of the multivariable models., Conclusion: We provide normative data for reliable cognitive change evaluation for all the tests of the MACFIMS, which includes the Symbol Digit Modalities Test and Brief International Cognitive Assessment in MS, two widely used tools for screening and monitoring cognition in MS. Our findings can significantly improve the interpretation of cognitive changes in MS., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: E.P. received compensation for travel grants, participation in advisory board and speaking activities from Biogen, Merck Serono, Sanofi, Teva, Roche, BMS Celgene, Janssen, and Novartis, and served on the editorial board of Frontiers in Neurology and Brain Sciences. M.P.A. served on scientific advisory boards for and has received speaker honoraria and research support from Biogen Idec, Merck Serono, Bayer Schering Pharma, and Sanofi Aventis, and serves on the editorial board of Multiple Sclerosis Journal and BMC Neurology. P.G., F.B., V.B., S.C., M.F., B.G., C.N., E.P., and R.G.V. declare that there is no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF